• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results

    5/6/24 12:48:16 PM ET
    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYPT alert in real time by email

    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.

    The Dow traded up 0.18% to 38,744.60 while the NASDAQ rose 0.69% to 16,267.82. The S&P 500 also rose, gaining, 0.61% to 5,158.84.

    Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Tech & Telecom Stocks Delivering High-Dividend Yields

    Leading and Lagging Sectors

    Energy shares rose by 1.5% on Monday.

    In trading on Friday, consumer staples shares fell by 0.4%.

    Top Headline

    Shares of TreeHouse Foods, Inc. (NYSE:THS) fell around 9% on Monday after the company reported mixed first-quarter financial results.

    The company reported a first-quarter FY24 sales of $820.70 million, beating the analyst consensus estimate of $797.18 million. Adjusted EPS of $(0.03) missed the analyst consensus of $(0.01).

    Equities Trading UP
                           

    • Perficient, Inc. (NASDAQ:PRFT) shares shot up 53% to $73.53 after the company disclosed an acquisition deal and first-quarter FY24 results.
    • Shares of Strong Global Entertainment, Inc. (NYSE:SGE) got a boost, surging 108% to $2.3783 fter FG Acquisition Corp. announced the proposed acquisition of Strong/MDI Screen Systems and the launch of Saltire Holdings.
    • XBP Europe Holdings, Inc. (NASDAQ:XBP) shares were also up, gaining 53% to $3.2350. XBP Europe Holdings was recently awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty’s Passport Office.

    Equities Trading DOWN

    • Lyra Therapeutics, Inc (NASDAQ:LYRA) shares dropped 87% to $0.5363 after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
    • Shares of GlycoMimetics, Inc (NASDAQ:GLYC) were down 79% to $0.3801 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).
    • EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) was down, falling 39% to $11.99 after the company’s Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.

    Also Check This Out: Top 2 Consumer Stocks That May Plunge This Quarter

    Commodities

    In commodity news, oil traded up 1.1% to $78.95 while gold traded up 1.2% at $2,335.40.

    Silver traded up 3.6% to $27.645 on Monday, while copper rose 1.4% to $4.6225.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 rose 0.53%, Germany's DAX rose 0.96% and France's CAC 40 gained 0.49%. Spain's IBEX 35 Index rose 0.58%, while London's FTSE 100 rose 0.51%.

    Asia Pacific Markets

    Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.1%, Hong Kong's Hang Seng Index jumping 0.55% and India's S&P BSE Sensex rising 0.02%.

    Economics

    No major economic reports will be released today.

    Now Read This: Netflix, Home Depot And More On CNBC’s ‘Final Trades‘

    Get the next $EYPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYPT
    $GLYC
    $LYRA
    $PRFT

    CompanyDatePrice TargetRatingAnalyst
    EyePoint Inc.
    $EYPT
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    GlycoMimetics Inc.
    $GLYC
    3/21/2025Overweight
    Cantor Fitzgerald
    EyePoint Inc.
    $EYPT
    1/7/2025$33.00Buy
    Citigroup
    Treehouse Foods Inc.
    $THS
    11/15/2024Overweight → Equal Weight
    Consumer Edge Research
    EyePoint Inc.
    $EYPT
    10/16/2024Sector Outperform
    Scotiabank
    EyePoint Inc.
    $EYPT
    8/28/2024$15.00Buy
    Jefferies
    GlycoMimetics Inc.
    $GLYC
    7/26/2024Buy → Hold
    TD Cowen
    Treehouse Foods Inc.
    $THS
    6/6/2024$37.00Neutral
    Mizuho
    More analyst ratings

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    SEC Filings

    View All

    SEC Form 8-K filed by Lyra Therapeutics Inc.

    8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

    4/10/26 8:59:10 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Lyra Therapeutics Inc.

    10-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

    3/31/26 5:16:33 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by XBP Global Holdings Inc.

    10-K - XBP Global Holdings, Inc. (0001839530) (Filer)

    3/31/26 9:11:02 AM ET
    $XBP
    EDP Services
    Technology

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/16/26 4:12:55 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Large owner Silver Point Capital L.P. bought $8,783,283 worth of shares (357,917 units at $24.54) (SEC Form 4)

    4 - TreeHouse Foods, Inc. (0001320695) (Issuer)

    2/12/26 8:35:21 PM ET
    $THS
    Packaged Foods
    Consumer Staples

    Director Klein Randal T bought $80,325 worth of shares (150,000 units at $0.54) (SEC Form 4)

    4 - XBP Global Holdings, Inc. (0001839530) (Issuer)

    8/19/25 8:23:45 AM ET
    $XBP
    EDP Services
    Technology

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cantor Fitzgerald initiated coverage on GlycoMimetics

    Cantor Fitzgerald initiated coverage of GlycoMimetics with a rating of Overweight

    3/21/25 8:14:54 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XBP Global Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    IRVING, Texas, March 30, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a multinational technology and services company orchestrating mission-critical systems that enable hyper-automation and digital transformation, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. Following the transformative acquisition of Exela Technologies BPA, LLC ("BPA") in July 2025, the Company is reporting results that reflect a significant transition period. To provide a clearer view of the combined business' performance, the Company has included pro forma metrics alongside reported GAAP results, with reconcilia

    3/30/26 9:00:00 AM ET
    $XBP
    EDP Services
    Technology

    XBP Global Pioneers Secure, On-Site Agentic AI for Next-Generation Healthcare Automation for Major French Health Insurance Institution

    PARIS, March 18, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, today announced that it has secured a €1 million plus contract to deploy a next-generation Agentic AI–powered Intelligent Document Processing (IDP) platform for a leading healthcare insurance provider in France. The engagement will introduce agentic AI workflows designed to automate complex, manual processes by interpreting and acting on unstructured data, improving classification, routing, and data ext

    3/18/26 9:32:43 AM ET
    $XBP
    EDP Services
    Technology

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 20,000 shares of EyePoint common stock to six new employees. The stock options were granted on March 13, 2026. The grants were approved by the Compensation Committee and made as an inducement material

    3/16/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Palasis Maria

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    4/3/26 4:05:04 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Cavalier Jason

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    4/3/26 4:05:03 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Duker Jay S.

    4 - EyePoint, Inc. (0001314102) (Issuer)

    3/24/26 4:05:54 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by XBP Europe Holdings Inc.

    SC 13D/A - XBP Europe Holdings, Inc. (0001839530) (Subject)

    11/21/24 8:41:09 PM ET
    $XBP
    EDP Services
    Technology

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Michael Campbell as Chief Commercial Officer

    – Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of

    2/18/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Merchants Bancorp Set to Join S&P SmallCap 600

    NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Merchants Bancorp (NASD: MBIN) will replace TreeHouse Foods Inc. (NYSE:THS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 11. Investindustrial S.A. and its affiliates are acquiring Treehouse Foods in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Feb 11, 2026 S&P SmallCap 600 Addition Merchants Bancorp MBIN Financial Feb 11, 2026 S&P SmallCap 600 Deletion TreeHouse Foods THS Consumer Staples ABOUT S&P DOW

    2/6/26 6:24:00 PM ET
    $MBIN
    $SPGI
    $THS
    Major Banks
    Finance
    Finance: Consumer Services
    Packaged Foods

    XBP Global Appoints Mike Shufeldt as Chief Revenue Officer to Accelerate Growth of XBP Americas

    IRVING, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, announced the appointment of Mike Shufeldt as Chief Revenue Officer (CRO), XBP Americas. In this role, Mr. Shufeldt will lead the revenue strategy and commercial execution, supporting the company's strategic shift toward accelerated, scalable, and client-centric growth in the Americas. The appointment highlights XBP Global's focus on strengthening its go-to-market model, driving solution-led sel

    1/28/26 8:00:00 AM ET
    $XBP
    EDP Services
    Technology

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYPT
    $GLYC
    $LYRA
    $PRFT
    Financials

    Live finance-specific insights

    View All

    XBP Global Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    IRVING, Texas, March 30, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. ("XBP Global" or "the Company") (NASDAQ:XBP), a multinational technology and services company orchestrating mission-critical systems that enable hyper-automation and digital transformation, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. Following the transformative acquisition of Exela Technologies BPA, LLC ("BPA") in July 2025, the Company is reporting results that reflect a significant transition period. To provide a clearer view of the combined business' performance, the Company has included pro forma metrics alongside reported GAAP results, with reconcilia

    3/30/26 9:00:00 AM ET
    $XBP
    EDP Services
    Technology

    EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

    WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A w

    2/25/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    XBP Global Holdings, Inc. Reports Third Quarter 2025 Results

    Third Quarter 2025 Highlights XBP Europe Holdings, Inc. ("XBP Europe") finalized the acquisition of Exela Technologies BPA, LLC ("Exela BPA") and changed its name to XBP Global Holdings, Inc. on July 29, 2025XBP Europe issued approximately 81.8 million shares for an equity valuation of the combined company of $585.7 million, or $4.98/share    Reported revenue1 totaled $209.1 million, a decline of 10.4% year-over-yearCombined Pro Forma Revenue2 totaled $220.4 million, a decline of 18.1% year-over-yearGross margin on a reported basis was 22.0%, a 310 basis point increase year-over-yearPro Forma Gross Margin2 of 21.9%, a 190 basis point increase year-over-yearPro Forma Adjusted EBITDA2,3 of $2

    11/14/25 4:01:00 PM ET
    $XBP
    EDP Services
    Technology